Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (NASDAQ:MRNA) announced the launch of two new vaccine development programs. The first is mRNA-1230, a combination respiratory vaccine targeting SARS-CoV-2, influenza, and RSV aimed at older adults. The second is mRNA-1287, a vaccine against four endemic human coronaviruses, which account for 10% to 30% of upper respiratory infections in adults. Moderna aims to address the global burden of respiratory diseases, particularly for older populations. This news underscores Moderna's commitment to expanding its mRNA portfolio and enhancing public health.
Moderna (NASDAQ: MRNA) has signed a new supply agreement with the Swiss Federal Government for seven million doses of its COVID-19 booster vaccine to be delivered in 2023. This adds to a previous agreement for seven million doses in the second half of 2022. CEO Stéphane Bancel emphasized the importance of booster doses in managing infection rates. The vaccine, SPIKEVAX, is authorized for individuals aged 12 and older, contributing to Moderna's robust portfolio in mRNA therapeutics. The company continues to expand its manufacturing capabilities and strategic collaborations.
Moderna, Inc. (MRNA) has submitted a request to the U.S. FDA to amend the emergency use authorization for its COVID-19 vaccine (mRNA-1273) to permit a fourth dose for adults aged 18 and older. The request aims to provide flexibility for healthcare providers and the CDC in administering additional booster doses, particularly for high-risk individuals. This submission relies on recent data from the U.S. and Israel, especially following the emergence of the Omicron variant. Moderna continues to collect real-world data to validate the vaccine's safety and effectiveness.
Moderna has received approval from Health Canada for its mRNA COVID-19 vaccine, SPIKEVAX, for children aged 6 to 11 years. This follows similar authorizations in both Australia and the European Union. The approval is based on data from the Phase 2/3 KidCOVE study, which demonstrated safety and efficacy in over 4,000 children. The vaccine displayed non-inferior antibody responses compared to older age groups. This marks a significant step in expanding vaccination efforts among younger populations.
Moderna, Inc. (NASDAQ:MRNA) has announced a deal with Japan's Ministry of Health to supply an additional 70 million doses of its COVID-19 booster vaccine in the second half of 2022. This agreement could increase the total contracted doses for Japan from 93 million to 163 million. The vaccine has received special approval for use in preventing COVID-19, with booster doses recommended for adults six months after the second dose. The agreement is contingent upon securing the necessary budget from the Ministry.
Moderna (Nasdaq:MRNA) announced the first participant has been dosed in its Phase 1 trial (HVTN 302) for an experimental HIV trimer mRNA vaccine (mRNA-1574). This multicenter, randomized trial aims to assess safety and immunogenicity in approximately 100 HIV-negative adults aged 18 to 55. Moderna's strategy involves using mRNA to induce protective HIV neutralizing antibodies. The trial is sponsored by the Division of AIDS at NIAID and aims to advance Moderna's capabilities in mRNA technology for HIV prevention.
Moderna has initiated a Phase 2 study of its Omicron-specific bivalent booster candidate (mRNA-1273.214), which combines mRNA-1273.529 and the original COVID-19 vaccine, mRNA-1273. The trial aims to enroll approximately 375 participants across 20 sites in the U.S. and will assess the immunogenicity, safety, and reactogenicity of the booster in adults. The study marks an extension of prior research and aligns with Moderna's commitment to adapt vaccines for emerging variants. Results will be shared with public health authorities ahead of the upcoming booster season.
Moderna, Inc. (NASDAQ:MRNA) will host its virtual Vaccines Day for analysts and investors on March 24, 2022, at 8:00 a.m. ET. The event will feature management presentations and insights from key opinion leaders regarding Moderna's mRNA vaccines and important developmental considerations. A live webcast will be accessible in the Investors section of the Moderna website, with a replay available for one year thereafter. Moderna has evolved to become a leading mRNA therapeutics and vaccines company, contributing significantly to pandemic efforts with its COVID-19 vaccine.
Moderna has unveiled a new global public health strategy through four key initiatives aimed at advancing mRNA vaccines for infectious diseases. The company plans to develop vaccines targeting 15 priority pathogens by 2025. Additionally, mRNA Access will allow researchers worldwide to utilize Moderna's mRNA technology. The company has also expanded its patent pledge, ensuring no enforcement in 92 low- and middle-income countries. Notably, Moderna will establish its first mRNA manufacturing facility in Kenya, investing up to $500 million to produce up to 500 million doses annually.
Moderna is investing up to $500 million to establish its first mRNA manufacturing facility in Kenya, aiming to produce up to 500 million doses of vaccines annually for the African continent. This initiative, made in partnership with the U.S. Government, focuses on enhancing local manufacturing capabilities to ensure equitable access to vaccines. The facility will initially handle drug substance manufacturing and may expand to include fill/finish services. Moderna's commitment is a significant step towards improving global health equity and preparing for future health crises.